Browse Drug Recalls
68 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 68 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 68 FDA drug recalls.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Jul 16, 2026 | Glycopyrrolate Injection, USP, 1 mg per 5 mL (0.2 mg per mL), 25 x 5 mL fill... | Presence of Particulate Matter: Hair was found in product | Class II | Fresenius Kabi USA, LLC |
| Jul 16, 2026 | Xylocaine (lidocaine HCl Injection, USP), 1%, 500 mg per 50 mL (10 mg per mL)... | Presence of Particulate Matter: Hair was found in products | Class II | Fresenius Kabi USA, LLC |
| Jul 16, 2026 | Lidocaine HCl Injection, USP, 2%, 100 mg per 5 mL (20 mg per mL), 25 Single D... | Presence of Particulate Matter: Hair was found in products | Class II | Fresenius Kabi USA, LLC |
| Jul 16, 2026 | Xylocaine (lidocaine HCl Injection, USP), 1%, 200 mg per 20 mL (10 mg per mL)... | Presence of Particulate Matter: Hair was found in products | Class II | Fresenius Kabi USA, LLC |
| Jul 16, 2026 | Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5... | Presence of Particulate Matter: Hair was found in products | Class II | Fresenius Kabi USA, LLC |
| May 14, 2026 | Epinephrine Injection, USP, 1mg/mL, 1 mL single-dose vial, Rx only, Fresenius... | Failed Impurities/Degradations Specifications | Class III | Fresenius Kabi USA, LLC |
| Mar 11, 2026 | 0.9% Sodium Chloride Injection, USP 900 mg per 100 mL (9 mg per mL), 1,000 mL... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
| Mar 11, 2026 | 0.9% Sodium Chloride Injection, USP, 900 mg per 100 mL (9 mg per mL) 250 mL i... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
| Mar 11, 2026 | 0.9% Sodium Chloride Injection, USP, 50 mL x60, Becton, Dickson and Company, ... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
| Mar 11, 2026 | 0.9% Sodium Chloride Injection, USP 0.9% (450 mg per 50 mL) (9 mg per mL) 50 ... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
| Mar 11, 2026 | 0.9% Sodium Chloride Injection, USP, 900 mg per 100 mL (9 mg per mL) 1,000 mL... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
| Mar 11, 2026 | 5% Dextrose Injection, USP 5 g per 100 mL (50 mg per mL) 100 mL in a 100 mL f... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
| Mar 11, 2026 | 5% Dextrose Injection, USP 12.5 g per 250 mL (50 mg per mL) 250 mL in a 250 m... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
| Mar 11, 2026 | 5% Dextrose Injection, USP 2.5 g per 50 mL (50 mg per mL) 50 mL in a 100 mL f... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
| Mar 11, 2026 | 0.9% Sodium Chloride Injection, USP, 900 mg per 100 mL (9 mg per mL) 100 mL i... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
| Mar 11, 2026 | 0.9% Sodium Chloride Injection, USP, (4,500 mg per 500 mL) (9 mg per mL) 500 ... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
| Mar 11, 2026 | 0.9% Sodium Chloride Injection, USP, 0.9% (900 mg per 100 mL) (9 mg per mL) 1... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
| Mar 11, 2026 | 0.9% Sodium Chloride Injection, USP 900 mg per 100 mL (9 mg per mL) 500 mL in... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
| Mar 11, 2026 | 0.45% Sodium Chloride Injection, USP, 1.125 grams per 250 mL (4.5 mg per mL),... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
| Mar 11, 2026 | 0.9% Sodium Chloride Injection, USP, (2,250 mg per 250 mL) (9 mg per mL) 250 ... | Lack of Assurance of Sterility | Class II | Fresenius Kabi USA, LLC |
| Nov 6, 2025 | Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2 mL vials, Rx only... | Microbial Contamination of Sterile Products; out of limit results obtained for endotoxin testing. | Class I | Fresenius Kabi USA, LLC |
| Nov 22, 2022 | Sensorcaine (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine... | Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product. | Class II | Fresenius Kabi USA, LLC |
| Nov 22, 2022 | Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP) with Epineph... | Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product. | Class II | Fresenius Kabi USA, LLC |
| Nov 22, 2022 | Sensorcaine (Bupivacaine HCl and Epinephrine Injection, USP) with Epinephrine... | Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product. | Class II | Fresenius Kabi USA, LLC |
| Mar 4, 2022 | Sodium Acetate Injection, USP, 400 mEq / 100 mL (4 mEq / mL), packaged in 2 t... | Presence of particulate matter: particulates composed of carbon and oxygen with varying amounts o... | Class I | Fresenius Kabi USA, LLC |
| Jun 25, 2021 | Xylocaine-MPF with Epinephrine 1:200,000, (Lidocaine HCl and Epinephrine Inje... | Low out of specification results for epinephrine assay. | Class II | Fresenius Kabi USA LLC |
| Dec 23, 2020 | Ketorolac Tromethamine Injection, USP, 30 mg per mL, packaged in 1 mL Single ... | Presence of Particulate Matter - found in reserve sample vials at the firm. | Class I | Fresenius Kabi USA, LLC |
| Dec 17, 2020 | Ketorolac Tromethamine Injection, USP, 60 mg per 2 mL (30 mg per mL), package... | Presence of Particulate Matter - found in reserve sample vials at the firm. | Class II | Fresenius Kabi USA, LLC |
| Dec 10, 2020 | Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP), 0.5%, 150 m... | Subpotent Drug: Low out-of-specification assay results for the epinephrine component. | Class II | Fresenius Kabi USA, LLC |
| Nov 17, 2020 | Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200 mcg / 50 mL (4 mcg... | Cross Contamination with other products: trace amounts of lidocaine | Class I | Fresenius Kabi USA, LLC |
| Nov 17, 2020 | DOXOrubicin Hydrochloride Injection, USP, 10 mg / 5 mL (2 mg / mL), 5 mL fill... | Cross Contamination with Other Products: trace amounts of octreotide found during testing | Class III | Fresenius Kabi USA, LLC |
| Jul 22, 2020 | Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200 mcg per 50 mL (4 m... | Cross Contamination with other products: trace amounts of lidocaine | Class I | Fresenius Kabi USA, LLC |
| Jul 13, 2020 | Fosaprepitant for Injection, 150 mg / vial in a 10 mL Single-Dose vial, Rx on... | Labeling Error: Label Error on Declared Strength: Carton label and product insert incorrectly sta... | Class III | Fresenius Kabi USA, LLC |
| Apr 20, 2020 | Ketorolac Tromethamine Injection, USP, 60 mg per 2 mL (30 mg per mL), package... | Presence of Particulate Matter - found in reserve sample vials at the firm. | Class II | Fresenius Kabi USA, LLC |
| Apr 20, 2020 | Ketorolac Tromethamine Injection, USP, 30 mg per mL, packaged in 1 mL Single ... | Presence of Particulate Matter - found in reserve sample vials at the firm. | Class I | Fresenius Kabi USA, LLC |
| Jun 28, 2019 | Fluorouracil Injection, USP, 5 g / 100 mL (50 mg / mL), 100 mL fill in a 100 ... | Presence of Particulate Matter; glass particulates | Class I | Fresenius Kabi USA, LLC |
| May 22, 2019 | Ondansetron Injection, USP, 40 mg / 20 mL, 20 mL vial, Rx Only, Fresenius Kab... | Failed Impurities/Degradation Specifications. | Class III | Fresenius Kabi USA, LLC |
| Nov 15, 2018 | SODIUM CHLORIDE INJECTION, USP, 0.9%, 10 mL Single Dose Vial, packaged in a 2... | Labeling Not Elsewhere Classified: Fresenius Kabi is taking this action due to an incorrect state... | Class I | Fresenius Kabi USA, LLC |
| Nov 15, 2018 | SODIUM CHLORIDE INJECTION, USP, 0.9%, 20 mL Single Dose Vial, packaged in a 2... | Labeling Not Elsewhere Classified: Fresenius Kabi is taking this action due to an incorrect state... | Class I | Fresenius Kabi USA, LLC |
| Jan 16, 2018 | Vecuronium bromide for Injection, 10 mg vials, Rx only, Mfd. for: Fresenius K... | Failed impurities/ degradation specifications: Out-of-specification (OOS) result for USP related ... | Class III | Fresenius Kabi USA, LLC |
| Oct 27, 2017 | Midazolam Injection, USP, Preservative Free, 2 mg / 2 mL (1 mg / mL), 24 X 2m... | Labeling: Label MIX-UP. Blister Packages, Labeled as Midazolam injection, USP, 2 mg / 2 ml, Cont... | Class I | Fresenius Kabi USA, LLC |
| Mar 16, 2017 | Fluphenazine Decanoate Injection, USP; 25 mg/mL, 5mL vials, Rx only, APP Phar... | Subpotent Drug | Class III | Fresenius Kabi USA, LLC |
| Mar 8, 2017 | hydrALAZINE HYDROCHLORIDE INJECTION, USP, 20 mg/mL, 1 mL Single Dose Vial, pa... | Temperature Abuse: Certain pieces of these lots distributed by McKesson Medical Surgical Inc. wer... | Class II | Mckesson Medical Surgical |
| Dec 16, 2016 | MIDAZOLAM INJECTION, USP, *25 mg/5 mL, (5 mg/ mL), 5 mL vials, 10 Vials per c... | Failed Impurities/Degradation Specifications | Class II | Fresenius Kabi USA, LLC |
| May 4, 2016 | OCTREOTIDE ACETATE INJECTION, 50 mcg (base)/mL (0.05 mg/mL), 1 mL Single Dose... | Failed Impuities/Degradation Specifications | Class II | Fresenius Kabi USA, LLC |
| May 4, 2016 | OCTREOTIDE ACETATE INJECTION, 50 mcg (base)/mL (0.05 mg/mL), 1 mL Single Dose... | Failed Impuities/Degradation Specifications | Class II | Fresenius Kabi USA, LLC |
| Apr 25, 2016 | Sensorcaine- MPF (Bupivacaine HCI Injection, USP), 0.75% in a 30 mL Single Do... | Presence of Particulate Matter: Glass particulate found in sterile injectable product | Class II | Fresenius Kabi USA, LLC |
| Apr 7, 2016 | Haloperidol Decanoate Injection, 50 mg/mL, 1 mL vial, Rx Only. Fresenius Kabi... | Failed Impurities/Degradation Specifications: Firm is recalling product due to an impurity out-of... | Class III | Fresenius Kabi USA, LLC |
| Apr 5, 2016 | Cisatracurium Besylate Injection, 20 mg per 10 mL (2 mg per mL), For intraven... | Incorrect/ Undeclared Excipient: Firm is recalling product due to an incorrect statement of Pres... | Class II | Fresenius Kabi USA, LLC |
| Jul 28, 2015 | Hydralazine Hydrochloride Injection, USP, 20 mg/mL, 1 mL fill, in a 2 mL; sin... | Incorrect Expiration Date: The "11/06" expiration date printed on the tray (secondary packaging) ... | Class III | Fresenius Kabi USA, LLC |
Frequently Asked Questions
When a drug safety issue is identified, through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks, the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.